2025/02/24 by Jose Portugal Gonzales, Luis Ostrosky‐Zeichner · 1 voice
Medicine · Immunology and Microbiology · #Antifungal resistance and susceptibility #Immunotoxicology and immune responses #Biosimilars and Bioanalytical Methods
paper · pdf · doi:10.1093/ofid/ofaf107
openalex publication_date 2025/02/24 · openalex created_date 2025/02/25 · openalex updated_date 2026/07/29
Abstract Illicit drug use in the United States continues to rise, alongside an increasing number of severe infections associated with drug use. Surveillance studies report that 28%–34% of candidemia cases are linked to intravenous drug use, with Candida albicans being the most commonly isolated species, followed by Candida parapsilosis and Candida glabrata. Marijuana use is associated with lung infections caused by Aspergillus and the Mucorales, showing a 3.5-fold increased risk of mold infections and a 2.2-fold increased risk for other fungal infections. Intravenous drug use also presents a recognized risk factor for Aspergillus and Mucorales infections. Additionally, substances like cannabis, methamphetamines, and opioids share metabolic pathways with triazoles, a class of antifungal, and terbinafine through the CYP enzyme system. These antifungal drugs strongly inhibit CYP3A4 and CYP2D6, leading to potential drug interactions, adverse effects, overdose risks, and even death.